Azenta, Inc.
HealthcareNASDAQ:AZTA · NASDAQ Global Select
+$0.13 today
Vol 0.52M · Avg 1.19M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-3.2%
avg 0.6%
ROIC
2.1%
avg -2.5%
ROA
-2.7%
avg 0.0%
Analysis
ROIC is currently the strongest return metric at 2.1% versus its period average of -2.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John Marotta | President, Chief Executive Officer & Director | $1.99M | — | 45 | $217,268.78 | 0.47% |
Lawrence Y. Lin | Executive Vice President & Chief Financial Officer | $1.13M | — | 49 | $79,655.00 | 0.17% |
Ginger Zhou | Advisor | $680,780.00 | — | 49 | $38,755.00 | 0.08% |
Olga Pirogova | Senior Vice President & Chief HR Officer | $660,694.00 | — | 52 | $33,038.00 | 0.07% |
Ephraim Starr | Senior Vice President, General Counsel & Corporate Secretary | $653,909.00 | — | 54 | $68,393.00 | 0.15% |
William E. Martin | Senior Vice President & President of Multiomics | — | — | 51 | $19,703.00 | 0.04% |
Alex Esmon | Vice President and General Manager of Sample Repository Solutions | — | — | — | — | — |
Michael Paulo | Vice President, Chief Information & Digital Officer | — | — | — | $13,042.00 | 0.03% |
Andrea O'Hara | Strategic Technical Specialist of Azenta Life Sciences | — | — | — | — | — |
Yvonne Perron | Vice President of Financial Planning & Analysis and Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$233,700.00
Sells
3
$71,225.36
Net Sentiment
+$162,474.64
Net buying
Most Active
Cornog William L
1 transactions
Analysis
Insiders reported 2 buys worth $233,700.00 and 3 sells worth $71,225.36 over the last 12 months. That adds up to net buying of $162,474.64. Cornog William L was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -53.4% | +15.2% (15yr)1 analysts |
| Revenue | N/A | N/A | +2.1% | +2.0% (15yr)2 analysts |
| Net Income | N/A | N/A | -53.0% | +12.3% (15yr)2 analysts |
| EBIT | N/A | N/A | +1.2% | +3.5% (15yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +2.1% over three years. Forward estimates point to EPS at +15.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
Establishment Labs Holdings Inc.
NASDAQ:ESTA
$2.42B
NovoCure Limited
NASDAQ:NVCR
$2.06B
Neogen Corporation
NASDAQ:NEOG
$1.98B
STAAR Surgical Company
NASDAQ:STAA
$1.41B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.28B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
Schrödinger, Inc.
NASDAQ:SDGR
$1.08B
Evotec SE
NASDAQ:EVO
$966.11M
Who manages AZTA?
Azenta, Inc. (AZTA) lists 10 active executives. The top listed executive is Ginger Zhou, Advisor.
Are AZTA insiders buying or selling?
Recent insider activity shows net buying of $14.24M.
Explore More
Continue the stock analysis
Jump to another research area for this company.